company background image
MRKR logo

Marker Therapeutics NasdaqCM:MRKR Stock Report

Last Price

US$4.34

Market Cap

US$38.5m

7D

-3.7%

1Y

410.0%

Updated

27 Mar, 2024

Data

Company Financials

Marker Therapeutics, Inc.

NasdaqCM:MRKR Stock Report

Market Cap: US$38.5m

MRKR Stock Overview

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.

MRKR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Marker Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Marker Therapeutics
Historical stock prices
Current Share PriceUS$4.34
52 Week HighUS$9.68
52 Week LowUS$0.67
Beta1.49
1 Month Change14.68%
3 Month Change-24.61%
1 Year Change410.00%
3 Year Change-80.65%
5 Year Change-93.22%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17
Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22
Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29
Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Marker Therapeutics EPS misses by $0.02

Nov 09

Shareholder Returns

MRKRUS BiotechsUS Market
7D-3.7%0.9%0.4%
1Y410.0%10.3%28.8%

Return vs Industry: MRKR exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: MRKR exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is MRKR's price volatile compared to industry and market?
MRKR volatility
MRKR Average Weekly Movement13.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: MRKR's share price has been volatile over the past 3 months.

Volatility Over Time: MRKR's weekly volatility has decreased from 19% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a67Juan Verahttps://www.markertherapeutics.com

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications.

Marker Therapeutics, Inc. Fundamentals Summary

How do Marker Therapeutics's earnings and revenue compare to its market cap?
MRKR fundamental statistics
Market capUS$38.53m
Earnings (TTM)-US$14.05m
Revenue (TTM)US$3.31m

11.6x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRKR income statement (TTM)
RevenueUS$3.31m
Cost of RevenueUS$10.42m
Gross Profit-US$7.11m
Other ExpensesUS$6.94m
Earnings-US$14.05m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin-214.60%
Net Profit Margin-424.20%
Debt/Equity Ratio0%

How did MRKR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.